Plasma copeptin and renal outcomes in patients with type 2 diabetes and albuminuria

Diabetes Care

Volumn 36, Issue 11, 2013, Pages 3639-3645

  Velho, Gilberto ^a   Bouby, Nadine ^b   Hadjadj, Samy ^a,c,d   Matallah, Nadia ^e   Mohammedi, Kamel ^a,e   Fumeron, Frédéric ^a,f   Potier, Louis ^b,e   Bellili Munoz, Naïma ^a   Taveau, Christopher ^b   Alhenc Gelas, François ^b   Bankir, Lise ^b   Marre, Michel ^a,e,f   Roussel, Ronan ^b,e,f  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c POITIERS UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ DE POITIERS   (France)

^e BICHAT HOSPITAL   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; COPEPTIN; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RAMIPRIL; VASOPRESSIN; ARGIPRESSIN; BIOLOGICAL MARKER; GLYCOPEPTIDE;

ACUTE HEART FAILURE; ADULT; AGED; ALBUMINURIA; ARTICLE; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HORMONE BLOOD LEVEL; HUMAN; INCIDENCE; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; URINARY EXCRETION; BLOOD; COMPLICATION; DIABETIC NEPHROPATHIES; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TEST; MIDDLE AGED;

AGED; ALBUMINURIA; ARGININE VASOPRESSIN; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 84891854098     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc13-0683     Document Type: Article

References (37)

1. National Kidney Foundation. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. Am J Kidney Dis 2012;60:850-886
2. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
3. Lewis EJ, Hunsicker LG, Clarke WR, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860
4. MacIsaac RJ, Ekinci EI, Kelly DJ, Jerums G. New treatments for diabetic chronic kidney disease. J Nephrol Therapeutic 2012;2(Suppl. 2). DOI: 10.4172/2161-0959.S2-006
5. Szinnai G, Morgenthaler NG, Berneis K, et al. Changes in plasma copeptin, the cterminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007;92:3973-3978
6. Balanescu S, Kopp P, Gaskill MB, MorgenthalerNG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab 2011;96:1046-1052
7. Zerbe RL, Vinicor F, Robertson GL. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 1979;28:503-508
8. Meijer E, Bakker SJ, Halbesma N, de Jong PE, Struck J, Gansevoort RT. Copeptin, a surrogate marker of vasopressin, is associated with microalbuminuria in a large population cohort. Kidney Int 2010;77: 29-36
9. Bardoux P, Bichet DG, Martin H, et al. Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003;18: 497-506
10. Bardoux P, Bruneval P, Heudes D, Bouby N, Bankir L. Diabetes-induced albuminuria: role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003;18: 1755-1763
11. Lièvre M, Marre M, Chatellier G, et al.; DIABHYCAR Study Group. The noninsulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. Control Clin Trials 2000;21: 383-396
12. MarreM, Lievre M, Chatellier G, Mann JF, Passa P, Ménard J; DIABHYCAR Study Investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study). BMJ 2004; 328:495
13. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-119
14. Marre M, Claudel JP, Ciret P, Luis N, Suarez L, Passa P. Laser immunonephelometry for routine quantification of urinary albumin excretion. Clin Chem 1987;33: 209-213
15. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
16. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496-509
17. Fenske W, Wanner C, Allolio B, et al.; German Diabetes, Dialysis Study Investigators. Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol 2011;22:782-790
18. Enhorning S, Bankir L, Bouby N, et al. Copeptin, a marker of vasopressin, in abdominal obesity, diabetes and microalbuminuria: the prospective Malmo Diet and Cancer Study cardiovascular cohort. Int J Obes (Lond) 2013;37:598-603
19. Meijer E, Bakker SJ, van der Jagt EJ, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6: 361-368
20. Boertien WE, Meijer E, Li J, et al.; Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease CRISP. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 2013;61:420-429
21. Boertien WE, Meijer E, Zittema D, et al. Copeptin, a surrogate marker for vasopressin, is associatedwith kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2012;27:4131-4137
22. Meijer E, Bakker SJ, de Jong PE, et al. Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients. Transplantation 2009;88:561-567
23. Strippoli GFM, Craig JC, Rochtchina E, Flood VM, Wang JJ, Mitchell P. Fluid and nutrient intake and risk of chronic kidney disease. Nephrology (Carlton) 2011;16: 326-334
24. Clark WF, Sontrop JM, Macnab JJ, et al. Urine volume and change in estimated GFR in a community-based cohort study. Clin J Am Soc Nephrol 2011;6:2634-2641
25. Perucca J, Bouby N, Valeix P, Bankir L. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol 2007;292:R700-R705
26. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009; 116:257-263
27. Bankir L, Bichet DG, Bouby N. Vasopressin V2 receptors, ENaC, and sodium reabsorption: a risk factor for hypertension? Am J Physiol Renal Physiol 2010; 299:F917-F928
28. Bouby N, Ahloulay M, Nsegbe E, Déchaux M, Schmitt F, Bankir L. Vasopressin increases glomerular filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996;7:842-851
29. Bouby N, Bachmann S, Bichet D, Bankir L. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990;258: F973-F979
30. Bouby N, Hassler C, Bankir L. Contribution of vasopressin to progression of chronic renal failure: study in Brattleboro rats. Life Sci 1999;65:991-1004
31. Bardoux P, Martin H, Ahloulay M, et al. Vasopressin contributes to hyperfiltration, albuminuria, and renal hypertrophy in diabetes mellitus: study in vasopressin-deficient Brattleboro rats. Proc Natl Acad Sci USA 1999;96:10397-10402
32. Bankir L, Bardoux P, Ahloulay M. Vasopressin and diabetes mellitus. Nephron 2001;87:8-18
33. Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19: 410-415
34. Brenner BM. Nephron adaptation to renal injury or ablation. AmJ Physiol 1985;249: F324-F337
35. Mann JF, Anderson C, Gao P, et al.; ONTARGET investigators. Dual inhibition of the renin-angiotensin system in high-risk diabetes and risk for stroke and other outcomes: results of the ONTARGET trial. J Hypertens 2013;31: 414-421
36. Wang CJ, Grantham JJ, Wetmore JB. The medicinal use of water in renal disease. Kidney Int 2013;8:45-53
37. Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 2013;9:223-239